期刊文献+

肽基脯氨酰顺反异构酶在子宫内膜癌组织中的表达及与PR蛋白的关系 被引量:1

Expression of pin1 in endometrial carcinoma and its relation with PR
下载PDF
导出
摘要 目的探讨肽基脯氨酰顺反异构酶(peptidyl prolyl cis-trans isomerase,Pin1)蛋白在子宫内膜癌组织中的表达与临床病理特征的关系,及其与病程相关蛋白的(PR)表达的相关性。方法回顾性分析湘雅医院 2010年2月~2012年10月收治50例子宫内膜癌临床病理资料,采用免疫组织化学方法对子宫内膜癌组织中pin1及PR蛋白的表达进行检测,结果采用卡方检验及Spearman相关系数法进行统计学分析。结果 pin1蛋白在子宫内膜癌中的阳性表达率为66%(33/50),其表达阳性率随着病理分化程度由高到低依次递减(高分化组93.3%,中分化组 84.6%,低分化组36.4%),浅肌层浸润组pin1阳性表达率(77.4%)显著高于深肌层浸润组(47.4%),淋巴结转移组pin1阳性表达率(28.6%)显著低于淋巴结未转移组(72.1%)。pin1与PR阳性表达呈现正相关(P〈0.05)。结论 pin1蛋白表达增高可能与子宫内膜癌的病理分化程度、肌层浸润深度及淋巴结转移有关,有望与PR一起成为预测子宫内膜癌患者治疗效果的一个重要的指标。 Objective To inverstigate the clinicopathologic significance of pin1 and PR in patients with endometrial adenocarcinoma. Methods The expression of pin1 and PR were investigated by immunohistochemistry in a total of 50 endometrial adenocarcinoma specimens. Results Pin1 was over expressed in 66%(33/50) of the cases. The expression rate decreased gradually with tumor differentiation(P〈0.05). In addition, pin1 expression was negatively correlated with lymph node metastasis and invasive depth of myometrium. Moreover, pin1 was positively correlated with PR expression. Conclusion Our results suggest that pin1 may play important roles in the tumorigenesis and migration of endometrial cancer. Pin1 expression may be considered as a prognostic marker as PR in patients with endometrial cancer.
出处 《南方医科大学学报》 CAS CSCD 北大核心 2013年第9期1403-1406,共4页 Journal of Southern Medical University
基金 湖南省卫生厅科研基金(B2012-005) 2012年湖南省青年骨干教师计划
关键词 子宫内膜癌 肽基脯氨酰顺反异构酶 PR endometrial adenocarcinoma pin1 PR
  • 相关文献

参考文献15

  • 1张瑜,张怡,林秋华.孕激素对人子宫内膜癌细胞系Ishikawa影响的蛋白质组学研究[J].南方医科大学学报,2006,26(8):1110-1113. 被引量:6
  • 2Ryo A, Liou YC, Lu KP, et al. Prolyl isomerase Pinl: a catalyst for oncogenesis and a potential therapeutic target in cancer[J]. J Cell Sci, 2003, 116(Pt 5): 773-83.
  • 3Lu KP. Prolyl isomerase Pinl as a molecular target for cancer diagnostics and therapeutics[J]. Cancer Cell, 2003, 4(3): 175-80.
  • 4Wulf G, Ryo A, Yc L, et al. The prolyl isomerase Pinl in breast development and cancer[J]. Breast Cancer Res, 2003, 5(2): 76-82.
  • 5Ayala G, Wang D, Wulf G, et al. The prolyl isomerase Pinl is a novel prognostic marker in human prostate cancer[J]. Cancer Res, 2003, 63(19): 6244-51.
  • 6Tan X, Zhou F, Wan J, et al. Pinl expression contributes to lung cancer: Prognosis and carcinogenesis[J]. Cancer Biol Ther, 2010, 9 (2): 111-9.
  • 7Ryo A, Nakamura M, Wulf G, et al. Pinl regulates turnover and subcellular localization of beta-catenin by inhibiting its interactionwith APC[J]. Nat Cell Biol, 2001, 3(9): 793-801.
  • 8Yeh E, Cunningham M, Arnold H, et al. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells[J]. Nat Cell Biol, 2004, 6(4): 308-18.
  • 9Yeh ES, Means AR. PIN1, the cell cycle and cancer[J]. Nat Rev Cancer, 2007, 7(5): 381-8.
  • 10Saegusa M, Hashimura M, Kuwata T. Pinl acts as a modulator of cell proliferation through alteration in NF-ld3 but not 13-catenin/ TCF4 signalling in a subset of endometrial carcinoma cells [J]. J Pathol, 2010, 222(4): 410-20.

二级参考文献23

  • 1[1]Cornelison TL,Trimble EL,Kosary CL,SEER data,corpus uteri cancer:Treatment trends versus survival for FIGO stage Ⅱ 1988-1994. Gynecol Oncol, 1999, 74: 350-355.
  • 2[2]Dai D, Kumat NS, Wolf DM, et al. Molecular tools to reestablish progestin control of endometrial cancer cell proliferation. Am J Obstet Gynecol, 2001,184:790-797.
  • 3[3]Satyaswaroop PG, Mortel R. Sex steroid receptors in endometrial carcinoma. Gynecol Oncol,1993, 50:278-280.
  • 4[4]Kumar NS, Richer J, Owen TR,et al. Selective down-regulation of progesterone receptor isoform B in poorly differentiated human endometrial cancer cells. Cancer Res, 1998,58:1860-1865.
  • 5[5]Lessey BA, Ilesanmi AO, Castelbaum AJ, et al. Characterization of the functional progesterone receptor in an endometrial adenocarcinoma cell line (Ishikawa): progesterone-induced expression of the α1 integrin. J Steroid Biochem Mol Biol, 1996,59:31-39.
  • 6[6]Beato M. Gene regulation by steroid hormones. Cell,1989,56: 335-344.
  • 7[7]McKenna NJ, Lanz RB, O'Malley BW. Nuclear receptor caregulators: cellular and molecular biology. Endocr Rev,1999, 20: 321-44.
  • 8[8]Rowan BG, O'Malley BW. Progesterone receptor coactivators. Steroids, 2000, 65: 545-549.
  • 9[9]Tibbetts TA, Mendoza-Meneses M,O'Maley BW,et al. Mutual and intercompartmental regulation of estrogen receptor and progesterone receptor expression in the mouse uterus. Bio Reprod, 1998,59: 1143-1152.
  • 10[10]Aronica SM, Katzenllenbogen BS. progesterone receptor regulation in uterine cells: stimulation by estrogen, cAMP, and insulin-like growth factor-Ⅰand supression by antiestrogens and protein kinase inhibitors. Endocrinology, 1991,128:2045-2052.

共引文献5

同被引文献16

  • 1李佳宇,滕月娥,刘云鹏.血管内皮生长因子C及其受体表达与乳腺癌淋巴结转移的相关性研究[J].中国医药指南,2007,5(4):85-87. 被引量:1
  • 2周金华,朱涛,李红雨,徐钢,卢运萍,马丁.PIN1反义核酸对乳腺癌MCF-7细胞增殖及周期的影响[J].肿瘤防治研究,2007,34(12):917-920. 被引量:1
  • 3Krishnan N,Titus MA,Thapar R.The prolyl isomerase pin1 regulates mRNA levels of genes with short half-lives by targeting specific RNA binding proteins[J].PLo S One,2014,9(1):e85427.
  • 4Khanal P,Kim G,Lim SC,et al.Prolyl isomerase Pin1 negatively regulates the stability of SUV39H1 to promote tumorigenesis inbreast cancer[J].FASEB J,2013,27(11):4606-4618.
  • 5Moore JD,Potter A.Pin1 inhibitors:Pitfalls,progress and cellular pharmacology[J].Bioorg Med Chem Lett,2013,23(15):4283-4291.
  • 6Rajbhandari P,Schalper KA,Solodin NM,et al.Pin1 modulates ERαlevels in breast cancer through inhibition of phosphorylationdependent ubiquitination and degradation[J].Oncogene,2014,33(11):1438-1447.
  • 7Lucchetti C,Caligiuri I,Toffoli G,et al.The prolyl isomerase Pin1acts synergistically with CDK2 to regulate the basal activity of estrogen receptorαin breast cancer[J].PLo S One,2013,8(2):e55355.
  • 8Aluise CD,Rose K,Boiani M,et al.Peptidyl-prolyl cis/transisomerase A1(Pin1)is a target for modification by lipid electrophiles[J].Chem Res Toxicol,2013,26(2):270-279.
  • 9张崇敬,张志辉,徐柏玲,王玉玲.Pin1及其抑制剂的研究进展[J].药学学报,2008,43(1):9-17. 被引量:14
  • 10李玲,陈平,连鸿凯,赵纪敏,马俊芬,董子明.Pinl抑制剂Juglone对食管癌EC1细胞增殖的抑制作用[J].世界华人消化杂志,2010,18(11):1147-1151. 被引量:3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部